Literature DB >> 2403775

Morphine-induced metabolic changes in human brain. Studies with positron emission tomography and [fluorine 18]fluorodeoxyglucose.

E D London1, E P Broussolle, J M Links, D F Wong, N G Cascella, R F Dannals, M Sano, R Herning, F R Snyder, L R Rippetoe.   

Abstract

Morphine sulfate effects (30 mg, intramuscularly) on cerebral glucose utilization and subjective self-reports were examined in 12 polydrug abusers by positron emission tomography and [fluorine 18]fluorodeoxyglucose in a double-blind placebo-controlled crossover study. During testing, subjects sat with eyes covered, listening to white noise and "beep" prompts. Morphine significantly reduced glucose utilization by 10% in whole brain and by about 5% to 15% in telencephalic areas and the cerebellar cortex, assuming no contribution of hypercapnia. When the contribution of PaCO2 (45 minutes after morphine was administered) was partialled out, significant morphine-induced reductions persisted in whole brain and six cortical areas. Irrespective of morphine, left-greater-than-right asymmetry occurred in the temporal cortex, and an interaction between hemisphere and drug was noted in the postcentral gyrus. In most cases, effects on glucose utilization were not significantly related to measures of euphoria.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2403775     DOI: 10.1001/archpsyc.1990.01810130075010

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  15 in total

Review 1.  Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex.

Authors:  Rita Z Goldstein; Nora D Volkow
Journal:  Am J Psychiatry       Date:  2002-10       Impact factor: 18.112

Review 2.  [Neuroimaging in substance abuse disorders].

Authors:  A de Mendelssohn; S Kasper; J Tauscher
Journal:  Nervenarzt       Date:  2004-07       Impact factor: 1.214

Review 3.  Neuropsychological consequences of opiate use.

Authors:  Staci A Gruber; Marisa M Silveri; Deborah A Yurgelun-Todd
Journal:  Neuropsychol Rev       Date:  2007-08-10       Impact factor: 7.444

4.  Use of Positron Emission Tomography to Measure Brain Activity Responses to Fentanyl Analgesia.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

5.  Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?

Authors:  Kenneth Blum; Thomas J H Chen; John Bailey; Abdalla Bowirrat; John Femino; Amanda L C Chen; Thomas Simpatico; Siobhan Morse; John Giordano; Uma Damle; Mallory Kerner; Eric R Braverman; Frank Fornari; B William Downs; Cynthia Rector; Debmayla Barh; Marlene Oscar-Berman
Journal:  Mol Neurobiol       Date:  2011-09-24       Impact factor: 5.590

Review 6.  Neuroimaging for drug addiction and related behaviors.

Authors:  Muhammad A Parvaz; Nelly Alia-Klein; Patricia A Woicik; Nora D Volkow; Rita Z Goldstein
Journal:  Rev Neurosci       Date:  2011-11-25       Impact factor: 4.353

Review 7.  Neural plasticity, human genetics, and risk for alcohol dependence.

Authors:  Shirley Y Hill
Journal:  Int Rev Neurobiol       Date:  2010       Impact factor: 3.230

8.  Cerebral metabolism and mood in remitted opiate dependence.

Authors:  Igor I Galynker; Daniel Eisenberg; John A Matochik; Enid Gertmenian-King; Lisa Cohen; Alane S Kimes; Carlo Contoreggi; Varughese Kurian; Monique Ernst; Richard N Rosenthal; James Prosser; Edythe D London
Journal:  Drug Alcohol Depend       Date:  2007-05-22       Impact factor: 4.492

Review 9.  Behavioral and neurological foundations for the moral and legal implications of intoxication, addictive behaviors and disinhibition.

Authors:  Robert F Leeman; Jon E Grant; Marc N Potenza
Journal:  Behav Sci Law       Date:  2009 Mar-Apr

10.  Opposing mechanisms underlying differential changes in brain oxygen and temperature induced by intravenous morphine.

Authors:  Ernesto Solis; Anum Afzal; Eugene A Kiyatkin
Journal:  J Neurophysiol       Date:  2018-09-05       Impact factor: 2.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.